ZBIO (Zenas BioPharma) FCF Yield % : -34.00 (As of Apr. 02, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Zenas BioPharma's Trailing 12-Month Free Cash Flow is $-119.81 Mil, and Market Cap is $352.37 Mil. Therefore, Zenas BioPharma's FCF Yield % for today is -34.00%.

The historical rank and industry rank for Zenas BioPharma's FCF Yield % or its related term are showing as below:

ZBIO' s FCF Yield % Range Over the Past 10 Years
Min: -41.13 Med: -9.05 Max: -3.97
Current: -34

During the past 3 years, the highest FCF Yield % of Zenas BioPharma was -3.97%. The lowest was -41.13%. And the median was -9.05%.

ZBIO's FCF Yield % is ranked worse than
68.42% of 1498 companies
in the Biotechnology industry
Industry Median: -15.56 vs ZBIO: -34.00

Zenas BioPharma's FCF Margin % for the quarter that ended in Dec. 2024 was -772.56%.

Zenas BioPharma FCF Yield % Historical Data

The historical data trend for Zenas BioPharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma FCF Yield % Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

FCF Yield %

-35.00

Zenas BioPharma Quarterly Data
	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial					-	-	-	-17.57	-45.14

Competitive Comparison of Zenas BioPharma's FCF Yield %

For the Biotechnology subindustry, Zenas BioPharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's FCF Yield % falls into.

Save Embed

;

Save Embed

;

Zenas BioPharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Zenas BioPharma's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-119.805	/	342.28467
	=	-35.00%

Zenas BioPharma's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-38.628	*	4	/	342.28467
	=	-45.14%

Zenas BioPharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Zenas BioPharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.